← Back to Search

Procedure

Axon Treatment Arm for Heart Failure (Rebalance-HF Trial)

N/A
Waitlist Available
Research Sponsored by Axon Therapies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

Summary

This trial is testing if destroying a specific nerve using a catheter can help patients with a certain type of heart failure. The goal is to see if this treatment can improve their heart function and symptoms.

Eligible Conditions
  • Diastolic Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Endpoint
Primary Safety Outcome
Secondary study objectives
Endpoints

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Axon Treatment ArmActive Control1 Intervention
Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
Group II: Sham Control ArmPlacebo Group1 Intervention
Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.

Find a Location

Who is running the clinical trial?

Axon Therapies, Inc.Lead Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
1 Trials studying Heart Failure
30 Patients Enrolled for Heart Failure
~17 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top